Market Place
Sourcing Support
La Jolla Announces Data on XERAVA to be Presented at IDWeek 2022
14 Oct 2022 //
BUSINESSWIRE
Innoviva Completes Acquisition of La Jolla Pharmaceutical
22 Aug 2022 //
BUSINESSWIRE
La Jolla Institute for Immunology Acquires the Carterra LSA Platform
01 Aug 2022 //
BUSINESSWIRE
Innoviva to Acquire La Jolla Pharmaceutical Company
11 Jul 2022 //
BUSINESSWIRE
La Jolla Announces Financial Results for 3 Months Ended March 31, 2022
16 May 2022 //
BUSINESSWIRE
La Jolla Announces Financial Results for 3 and 12 Months Ended December 31, 2021
09 Mar 2022 //
BUSINESSWIRE
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
17 Nov 2021 //
BUSINESSWIRE
La Jolla Pharmaceutical Company Announces Financial Results for the Three
04 Nov 2021 //
BUSINESSWIRE
Tony Hodges, M.D., FACP, FCCP, Appointed CMO of La Jolla Pharmaceutical Company
10 Sep 2021 //
BUSINESSWIRE
La Jolla Pharmaceutical Company Announces Financial Results
05 Aug 2021 //
BUSINESSWIRE
La Jolla Pharmaceutical Company Announces Financial Results for Three Months
07 May 2021 //
BUSINESSWIRE
La Jolla Announces Financial Results for 3 & 12 Months Ended December 31, 2020
08 Mar 2021 //
BUSINESSWIRE
La Jolla Company Announces Exclusive Licensing Agreement for GIAPREZA™
12 Jan 2021 //
NASDAQ
La Jolla Announces Financial Results for the Three and Six Months
06 Aug 2020 //
GLOBENEWSWIRE
Tetraphase deal done, La Jolla Pharmaceutical taps Larry Edwards as CEO
30 Jul 2020 //
ENDPTS
La Jolla Company Announces the Closing of Acquisition of Tetraphase
28 Jul 2020 //
GLOBENEWSWIRE
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
24 Jun 2020 //
BUSINESSWIRE
La Jolla feels the burn of rival malaria approval; With another $10B, Bayer
28 May 2020 //
ENDPTS
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II)
07 Apr 2020 //
BUSINESSINSIDER
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.